Saturday, January 31, 2026

In Detail Full day, Saturday, January 31, 2026, Timezone: America/Chicago

Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

AI Summary: Summit Therapeutics announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for Ivonescimab—intended for patients with EGFR‑mutated non‑small cell lung cancer who have progressed after TKI therapy. The regulatory nod signals a promising step forward in targeted lung cancer treatment.

India says it has contained Nipah virus outbreak as some Asian countries ramp up health screenings

go - Indian authorities have contained a Nipah virus outbreak after confirming two cases in eastern West Bengal state

AI Summary: Indian health authorities report that a recent Nipah virus outbreak in West Bengal – marked by two confirmed cases – has been successfully contained. In response, airports and health officials have stepped up screenings to curb further spread, highlighting growing regional vigilance in controlling the outbreak.

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

AI Summary: U.S. regulators have just cleared Intellia Therapeutics’ Phase 3 study of a gene‐editing therapy intended to treat a genetic nerve disorder, effectively rescinding a clinical hold. This development opens the door to renewed patient enrolment and further evaluation of the treatment’s safety and effectiveness.

CMS official defends flat Medicare Advantage rate proposal for 2027

Rebecca Pifer Parduhn / healthcaredive - Medicare director Chris Klomp said the Trump administration is “massively” in support of MA as health insurers cry foul over the meager rate update.

AI Summary: A CMS official defended the administration’s plan to freeze Medicare Advantage rate adjustments for 2027 despite industry outcry. Critics argue the flat-rate approach may hurt patient benefits while officials insist it brings consistency amid a contentious policy environment.